An association between autoreactive antibodies and anti-interferon-β antibodies in multiple sclerosis

Abstract

Approximately 5—25% of interferon-β (IFN-β) treated multiple sclerosis (MS) patients develop anti-IFN-β neutralizing antibodies (NAb) but the patient-specific variables associated with the risk of developing anti-IFN-β antibodies are poorly understood. Anti-IFN-β NAb are a subset of anti-IFN-β binding antibodies (BAb) and all patients with NAb generally have high levels of associated BAb. The purpose of this research was to assess the association between autoreactive antibodies (ARAB) and the risk of developing anti-IFN-β BAb in MS patients. This was a retrospective study that included consecutive patients diagnosed with clinically definite MS evaluated at our center and considered appropriate for IFN-β therapy. The patients were tested for various subtypes of antiphospholipid antibodies (APLA) including anti-phosphatidylethanolamine (APE), anti-phosphatidylserine (APS), and anti-cardiolipin (ACA) antibodies, and other ARAB, antinuclear and anti-neutrophilic cytoplasmic antibodies, anti-thyroid peroxidase antibodies (ATA), anti-SS-A and anti-SS-B antibodies. BAb levels were assessed using a commercial binding ELISA assay. A total of 33 patients (mean age: 45.4 years, 85% female) were enrolled; 15 patients were negative and 18 patients were positive for BAb. APLA or ATA were present in 95% (17 of 18 patients) of patients positive for BAb. In comparison, APLA or ATA occurred in only 27% (four of 15 patients) of patients in the BAb negative group. The associations between the occurrence of BAb and the occurrence of high APLA or ATA were significant (χ2 = 13.4, P<0.001in Fisher exact test). The odds ratio for the association was 46.8 (with a 95% confidence interval range of 4.6—475). No significant correlations were found for other ARAB. The presence of autoreactive antibodies, particularly APLA and ATA is associated with increased risk of occurrence of IFN-β BAb in MS patients on long-term IFN-β therapy. Multiple Sclerosis 2007; 13: 895—899. http://msj.sagepub.com

Keywords

antiphospholipid antibody antithyroid antibody autoreactive antibody beta-interferon binding antibody multiple sclerosis

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655—61.

Rudick RA , Simonian NA Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266—72.

Jacobs LD , Cookfair DL , Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285—94.

Francis GS , Rice GP , Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48—55.

Kappos L. , Clanet M. , Sandberg-Wollheim M. et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40—47.

Ross C. , Clemmesen KM , Svenson M. et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706—12.

Bertolotto A. , Malucchi S. , Sala A. et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73: 148—53.

De Keyser J. Autoimmunity in multiple sclerosis. Neurology 1988; 38: 371—74.

Barned S. , Goodman AD , Mattson DH Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology 1995; 45: 384—85.

10.

Collard RC , Koehler RP , Mattson DH Frequency and significance of antinuclear antibodies in multiple sclerosis . Neurology 1997; 49: 857—61.

11.

McDonald WI , Compston A. , Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—27.

12.

Seyfert S. , Klapps P. , Meisel C. , Fischer T. , Junghan U. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand 1990; 81: 37—42.

13.

Stickler M. , Valdes AM , Gebel W. et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immun 2004; 5: 1—7.

14.

Ross C. , Clemmesen KM , Sorensen PS , Koch-Henriksen N. , Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39—46.

15.

Colosimo C. , Pozzilli C. , Frontoni M. et al. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 1997 ; 96: 372—74.

16.

Durelli L. , Ferrero B. , Oggero A. et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001; 86: 3525—32.

17.

Durelli L. , Ferrero B. , Oggero A. et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 2001; 57: 1363—70.

18.

Durelli L. , Oggero A. , Verdun E. et al. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study. J Neurol Sci 2001; 193: 17—22.

19.

Verdun E. , Isoardo G. , Oggero A. et al. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 2002; 22: 245—55.

20.

Angelucci F. , Mirabella M. , Frisullo G. , Caggiula M. , Tonali PA , Batocchi AP Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. Dis Markers 2005; 21(2): 49—55.

21.

Pozzilli C. , Antonini G. , Bagnato F. , et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249(1): 50—56.